Self SG - Search Results

1

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.

Hudgens MG, Self SG, Chiu YL, Russell ND, Horton H, McElrath MJ. Hudgens MG, et al. Among authors: self sg. J Immunol Methods. 2004 May;288(1-2):19-34. doi: 10.1016/j.jim.2004.01.018. J Immunol Methods. 2004. PMID: 15183082

2

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Russell ND, et al. Among authors: self sg. J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):203-12. doi: 10.1097/01.qai.0000248356.48501.ff. J Acquir Immune Defic Syndr. 2007. PMID: 17106277 Free PMC article. Clinical Trial.

3

On the analysis of viral load endpoints in HIV vaccine trials.

Hudgens MG, Hoering A, Self SG. Hudgens MG, et al. Among authors: self sg. Stat Med. 2003 Jul 30;22(14):2281-98. doi: 10.1002/sim.1394. Stat Med. 2003. PMID: 12854093

4

Statistical evaluation of HIV vaccines in early clinical trials.

Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND. Moodie Z, et al. Among authors: self sg. Contemp Clin Trials. 2006 Apr;27(2):147-60. doi: 10.1016/j.cct.2005.11.008. Epub 2006 Jan 19. Contemp Clin Trials. 2006. PMID: 16426900

5

HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features.

Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG. Li F, et al. Among authors: self sg. Curr HIV Res. 2007 Jan;5(1):97-107. doi: 10.2174/157016207779316260. Curr HIV Res. 2007. PMID: 17266561

6

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.

Kublin JG, Morgan CA, Day TA, Gilbert PB, Self SG, McElrath MJ, Corey L. Kublin JG, et al. Among authors: self sg. Clin Investig (Lond). 2012 Mar;2(3):245-254. doi: 10.4155/cli.12.8. Clin Investig (Lond). 2012. PMID: 23243491 Free PMC article.

7

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.

Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L; HIV Vaccine Trials Network. Montefiori DC, et al. J Infect Dis. 2004 Dec 1;190(11):1962-9. doi: 10.1086/425518. Epub 2004 Oct 28. J Infect Dis. 2004. PMID: 15529261

8

Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.

Malhotra U, Li F, Nolin J, Allison M, Zhao H, Mullins JI, Self S, McElrath MJ. Malhotra U, et al. J Virol. 2007 May;81(10):5225-37. doi: 10.1128/JVI.02564-06. Epub 2007 Feb 28. J Virol. 2007. PMID: 17329342 Free PMC article.

9

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. Among authors: self sg. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

10

Endpoints in vaccine trials.

Hudgens MG, Gilbert PB, Self SG. Hudgens MG, et al. Among authors: self sg. Stat Methods Med Res. 2004 Apr;13(2):89-114. doi: 10.1191/0962280204sm356ra. Stat Methods Med Res. 2004. PMID: 15068256

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

175 results

Search Page

Filters